PCSK9 Inhibitor
- Name
- PCSK9 Inhibitor
- Accession Number
- DBCAT003524
- Description
Agents that inhibit Proprotein Convertase Subtilisin/Kexin Type 9 (see PROPROTEIN CONVERTASE 9 (PCSK9)), an enzyme that plays an important role in the degradation of the LDL receptors. It favors LDL catabolism and reduces plasma LDL-cholesterol (LDL_C) level.
- Drugs
Drug Drug Description Alirocumab A PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C). Evolocumab A PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures. Inclisiran A PCSK9-targeting short interfering RNA (siRNA) that lowers plasma LDL-cholesterol levels. - Drugs & Drug Targets
Drug Target Type Alirocumab Proprotein convertase subtilisin/kexin type 9 target Evolocumab Proprotein convertase subtilisin/kexin type 9 target Inclisiran Proprotein convertase subtilisin/kexin type 9 target